FA
CLGN icon

Friess Associates’s CollPlant Biotechnologies CLGN Stock Holding History

Friess Associates’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-235,092
Closed -$4.99M – 87
2021
Q2 		$4.99M Sell
235,092
-14,999
-6% -$240K 1.88% 17
2021
Q1 		$3.36M Buy
+250,091
New +$3.77M 1.31% 28

Other funds holding CLGN

IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
WC
Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Friess Associates's CLGN Position: Q3 2021 in Review

Friess Associates sold out of CollPlant Biotechnologies (CLGN) in Q3 2021, closing a stake of 235,092 shares — an estimated $4.99M sold.

Friess Associates first reported a position in CLGN in Q1 2021 and held it in 2 quarters. The position peaked at $4.99M in Q2 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q3 2021.

  • Friess Associates reported no remaining CollPlant Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Friess Associates sold 235,092 CollPlant Biotechnologies shares in Q3 2021, an estimated $4.99M.
  • Friess Associates first reported a position in CollPlant Biotechnologies in Q1 2021 and held it in 2 quarters.
  • Friess Associates's CollPlant Biotechnologies position peaked at $4.99M in Q2 2021.
  • 15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q3 2021.

Based on Friess Associates's 13F filing for Q3 2021, filed 12 Nov 2021.